A composition comprising a substituted tricyclic PRMT5 inhibitor and its use

By optimizing the pharmaceutical composition containing compound (I), the stability and absorption issues of PRMT5 inhibitor formulations have been resolved, achieving high drug dissolution and bioavailability, making it suitable for the treatment of PRMT5-mediated diseases.

CN115192576BActive Publication Date: 2026-11-17NANJING SANHOME PHARMACEUTICAL CO LTD
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202210381816.8
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2021-04-13
Filing Date
2022-04-12
Publication Date
2026-11-17
Estimated Expiration
2042-04-12

AI Technical Summary

Technical Problem

Existing PRMT5 inhibitor formulations suffer from poor long-term stability, inadequate drug absorption, and low bioavailability, which hinders their application in the treatment of PRMT5-related diseases.

Method used

A pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt, solvate, crystal, disintegrant, lubricant, and filler thereof is provided, wherein the composition ratio and preparation method are optimized to improve the dissolution and stability of the drug.

Benefits of technology

It achieves complete drug dissolution, improves bioavailability, and remains stable under high humidity, high temperature and light conditions, making it suitable for clinical drug use.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN115192576B_ABST
    Figure CN115192576B_ABST
Patent Text Reader

Abstract

This invention belongs to the field of pharmaceutical preparations and relates to a composition comprising a substituted tricyclic PRMT5 inhibitor and its use, specifically relating to a pharmaceutical composition comprising (R)-7'-((2-acetyl-2-azaspiro[3.3]hept-6-yl)amino)-2'-(3-(3,4-dihydroisoquinoline-2(1H)-yl)-2-hydroxypropyl)-2',3'-dihydro-1'H-spiro[cyclopropane-1,4'-[2,6]naphthidium]-1'-one or its solvates or crystals thereof. The pharmaceutical composition provided by this invention exhibits complete dissolution, good stability, good absorption properties, and high relative bioavailability.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention belongs to the field of pharmaceutical preparations and relates to a composition comprising a substituted tricyclic PRMT5 inhibitor and its use, specifically relating to a pharmaceutical composition comprising (R)-7'-((2-acetyl-2-azaspiro[3.3]hept-6-yl)amino)-2'-(3-(3,4-dihydroisoquinoline-2(1H)-yl)-2-hydroxypropyl)-2',3'-dihydro-1'H-spiro[cyclopropane-1,4'-[2,6]naphthidine]-1'-one or a solvate or crystal thereof. Background Technology

[0002] DNA modification plays a central role in triggering gene expression programs at different stages of cell growth and development. Among these, arginine methylation plays a crucial role in cellular processes including signal transduction, transcription, RNA processing, DNA recombination, and repair. Protein arginine methyltransferases (PRMTs) catalyze the methylation of specific arginine residues by transferring a methyl group from S-adenosylmethionine (SAM) to the guanidine nitrogen of arginine. Based on their catalytic arginine methylation mechanisms, PRMTs can be classified into three types: Type I (PRMT 1, 2, 3, 4, 6, and 8) catalyze both monomethylation and asymmetric dimethylation; Type II (PRMT 5 and PRMT 9) catalyze both monomethylation and symmetric dimethylation; and Type III (PRMT 7) performs only monomethylation.

[0003] PRMT5 specifically binds to methyltransferase complex protein 50 (MEP50), symmetrically methylating histones H3 and H4 and regulating transcription of specific target genomes. PRMT5-catalyzed symmetrical dimethylation of histone H3 arginine 8 (R8) and H4R3 has been shown to inhibit the expression of several tumor suppressor genes, such as tumor suppressor gene 7 (ST7), the retinoblastoma (RB) tumor suppressor gene family, and receptor O-type protein tyrosine phosphatase (PTPROt).

[0004] In addition to its ability to methylate histones, PRMT5 can also methylate several important transcription factors, enabling them to play crucial roles in cellular regulation. PRMT5 can methylate p53 and alter its DNA-binding activity, thereby triggering changes in the gene expression program controlled by p53. PRMT5 also shows methylation of N-MYC, altering its protein stability and enhancing its oncogenic activity in neuroblastoma. PRMT5 can also directly methylate transcription factors, including E2F-1 and NF-κB / p65, inducing the expression of their target genes. PRMT5 can modify not only nuclear transcription factors but also methylate cytoplasmic proteins such as golgin and ribosomal protein S10 (RPS10). Therefore, in addition to its ability to directly regulate its own target genes, PRMT5 can also indirectly affect global gene expression through the symmetrical methylation of key transcription factors, thereby influencing cell growth, proliferation, and differentiation.

[0005] Numerous studies have confirmed PRMT5 overexpression in various types and invasive cancers, including B-cell and T-cell lymphomas, metastatic melanomas, neuroblastomas and glioblastomas, germ cell tumors, ovarian cancer, nasopharyngeal carcinoma, breast cancer, colorectal cancer, and gastric cancer. Current research indicates that PRMT5 plays a crucial role in controlling cell growth and proliferation, and its overexpression promotes cell transformation.

[0006] Enhanced PRMT5 expression in cancer cells is associated with transcriptional silencing of its target tumor suppressor genes. PRMT5 promotes cancer cell growth by inducing global chromatin changes through methylation of promoter histones H3R8 and H4R3 and by modifying specific arginine residues of key transcription factors, including E2F1 and NF-κB / p65. PRMT5 also interacts with programmed cell death 4 (PDCD4), causing it to become methylated at R110 and lose its tumor suppressor activity in MCF-7 cells. In summary, PRMT5 overexpression may enable it to interact with growth-promoting and tumor suppressor proteins, thereby favoring cancer cell growth, survival, and metastasis.

[0007] In summary, PRMT5 inhibitors have a clear mechanism of action in treating tumors and related diseases, and have great potential to become a new treatment method in the field of cancer treatment. Therefore, it is necessary to develop safer and more effective PRMT5 inhibitors to meet clinical needs. Summary of the Invention

[0008] The inventors of this invention have discovered a substituted tricyclic PRMT5 inhibitor with the following compound structure as shown in formula (I), and its chemical name is (R)-7'-((2-acetyl-2-azaspiro[3.3]hept-6-yl)amino)-2'-(3-(3,4-dihydroisoquinoline-2(1H)-yl)-2-hydroxypropyl)-2',3'-dihydro-1'H-spiro[cyclopropane-1,4'-[2,6]naphthidium]-1'-one (hereinafter referred to as "compound of formula (I)").

[0009]

[0010] The inventors of this invention have discovered that compounds of formula (I) or pharmaceutically acceptable salts, hydrates, solvates or crystals thereof exhibit significant inhibitory activity against PRMT5 and are very promising therapeutic agents for PRMT5-related diseases.

[0011] To date, no suitable formulations of compounds of formula (I) or their isomers or pharmaceutically acceptable salts have been reported. It is well known in the art that many challenges exist in the formulation of such preparations, such as long-term stability, control of related substances, drug absorption, and bioavailability. These challenges are determined by a variety of factors, including many factors affecting drug absorption, such as drug dissolution or release from the formulation, drug solubility under physiological conditions, and permeability in the gastrointestinal tract.

[0012] Therefore, it is necessary to study compounds of formula (I) or their derivatives to provide suitable formulations that meet clinical needs, such as formulations with improved flowability, good dissolution and stability under light conditions.

[0013] One object of the present invention is to provide a pharmaceutical composition comprising (a) a compound of formula (I) or a pharmaceutically acceptable salt, solvate or crystal thereof; and (b) a disintegrant, wherein the pharmaceutical composition of the present invention can be formulated into a completely soluble form with high bioavailability.

[0014] Another object of the present invention is to provide a pharmaceutical preparation containing the pharmaceutical composition of the present invention.

[0015] Another object of the present invention is to provide the use of the pharmaceutical compositions of the present invention in the preparation of medicaments for treating PRMT5-mediated diseases.

[0016] To achieve the above objectives, the present invention provides the following technical solution:

[0017] In one aspect, the present invention provides a pharmaceutical composition comprising:

[0018] (a) A compound of formula (I) or a pharmaceutically acceptable salt, solvate or crystal thereof.

[0019]

[0020] and (b) disintegrants.

[0021] In some specific embodiments, the pharmaceutical composition of the present invention comprises a compound of formula (I) or a pharmaceutically acceptable salt, solvate or crystal, disintegrant, lubricant and filler thereof, wherein, based on the amount of the compound of formula (I), the compound of formula (I) or a pharmaceutically acceptable salt, solvate or crystal thereof accounts for about 1% to 80% (by weight), preferably about 1% to 40% (by weight), and more preferably about 2% to 20% (by weight) of the total weight of the pharmaceutical composition.

[0022] In some specific embodiments, the pharmaceutical composition of the present invention comprises a compound of formula (I) or a pharmaceutically acceptable salt, solvate, or crystallizer and disintegrant thereof, wherein the disintegrant is selected from one or more of sodium carboxymethyl starch (CMS-Na), crospovidone, crospovidone carboxymethyl cellulose (CCNa), and low-substituted hydroxypropyl cellulose (L-HPC), preferably one or more of sodium carboxymethyl starch, crospovidone carboxymethyl cellulose, and low-substituted hydroxypropyl cellulose, and more preferably crospovidone carboxymethyl cellulose. It is known in the art that, within a certain range, increasing the disintegrant dosage can promote the disintegration of capsules and the dissolution of the drug; however, beyond a certain amount, its pro-disintegration effect gradually weakens, and may even hinder the dissolution of the drug. Therefore, it is necessary to study the content and method of use of the disintegrant to achieve the best disintegration effect. In some embodiments, the disintegrant in the pharmaceutical composition provided by the present invention accounts for about 1% to 30% (weight / weight) of the total weight of the pharmaceutical composition, preferably 2% to 15% (weight / weight), and more preferably 3% to 5% (weight / weight). The inventors of this invention have discovered that formulations prepared using the pharmaceutical composition of this invention containing the above-mentioned disintegrant can significantly improve the dissolution of compound (I), and the formulations are stable under high humidity, high temperature, light, and accelerated and long-term testing conditions, with few impurities.

[0023] In some embodiments, the pharmaceutical composition provided by the present invention further comprises a lubricant, i.e., the pharmaceutical composition provided by the present invention comprises a compound of formula (I) or a pharmaceutically acceptable salt, solvate or crystal, disintegrant and lubricant thereof, wherein the disintegrant has the definition described above, and the lubricant is selected from one or more of magnesium stearate, calcium stearate, stearic acid, zinc stearate, sodium stearate fumarate, talc, polyethylene glycol, glyceryl behenate, glyceryl monostearate, glyceryl palmitate stearate, sodium lauryl sulfate and hydrogenated vegetable oil. More preferably, the lubricant is selected from one or more of magnesium stearate, calcium stearate, zinc stearate, stearic acid, polyethylene glycol, talc, sodium stearate fumarate and glyceryl behenate. In some embodiments of the present invention, the lubricant in the pharmaceutical composition provided by the present invention accounts for about 0% to 10% (weight / weight) of the total weight of the pharmaceutical composition, preferably about 0.1% to 5% (weight / weight), more preferably about 0.3% to 2% (weight / weight), and even more preferably about 0.5% to 1.0% (weight / weight).

[0024] In some embodiments, the pharmaceutical composition provided by the present invention further comprises a filler, namely, a compound of formula (I) or a pharmaceutically acceptable salt, solvate or crystal, disintegrant, lubricant and filler thereof, wherein the disintegrant and lubricant have the definitions described above, and the filler is selected from one or more of microcrystalline cellulose (MCC), powdered cellulose, magnesium carbonate, calcium sulfate dihydrate, pregelatinized starch, mannitol (MAN), starches, lactose (LAC), sugars, celluloses and inorganic salts. In some preferred embodiments, the pharmaceutical composition of the present invention comprises two or more fillers, one of which is selected from microcrystalline cellulose, powdered cellulose, magnesium carbonate, calcium sulfate dihydrate and pregelatinized starch, and the other fillers are selected from one or more of mannitol, starches, lactose, sugars, celluloses and inorganic salts. More preferably, the other fillers are selected from one or more of starch, glucose binders, glucose, lactose, dextrin, fructose, maltose, sorbitol and mannitol. In some embodiments of the present invention, the filler in the pharmaceutical composition provided by the present invention accounts for about 0% to 95% (weight / weight) of the total weight of the pharmaceutical composition, preferably about 40% to 95% (weight / weight), and more preferably about 75% to 94% (weight / weight). In some embodiments, the pharmaceutical composition of the present invention further comprises microcrystalline cellulose and lactose, wherein the weight ratio of microcrystalline cellulose to lactose is about 8:1 to about 1:1, preferably about 6:1 to about 2:1, and more preferably about 4:1.

[0025] In some preferred embodiments, the pharmaceutical composition of the present invention comprises a compound of formula (I) or a pharmaceutically acceptable salt, solvate or crystal, disintegrant, lubricant and filler, wherein, based on the amount of the compound of formula (I), the compound of formula (I) or a pharmaceutically acceptable salt, solvate or crystal comprises about 1% to 80% (by weight) of the total weight of the pharmaceutical composition, the disintegrant comprises about 1% to 30% (by weight) of the total weight of the pharmaceutical composition, the lubricant comprises about 0% to 10% (by weight) of the total weight of the pharmaceutical composition, and the filler comprises about 0% to 95% (by weight) of the total weight of the pharmaceutical composition. More preferably, the pharmaceutical composition of the present invention comprises a compound of formula (I) or a pharmaceutically acceptable salt, solvate or crystal, disintegrant, lubricant and filler, wherein, based on the amount of the compound of formula (I), the compound of formula (I) or a pharmaceutically acceptable salt, solvate or crystal comprises about 1% to 40% (by weight) of the total weight of the pharmaceutical composition, the disintegrant comprises about 2% to 15% (by weight) of the total weight of the pharmaceutical composition, the lubricant comprises about 0.1% to 5% (by weight) of the total weight of the pharmaceutical composition, and the filler comprises about 40% to 95% (by weight) of the total weight of the pharmaceutical composition. More preferably, the pharmaceutical composition of the present invention comprises a compound of formula (I) or a pharmaceutically acceptable salt, solvate or crystal, disintegrant, lubricant and filler, wherein, based on the amount of the compound of formula (I), the compound of formula (I) or a pharmaceutically acceptable salt, solvate or crystal comprises about 2% to 20% (by weight) of the total weight of the formulation, the disintegrant comprises about 3% to 5% (by weight) of the total weight of the pharmaceutical composition, the lubricant comprises about 0.3% to 2% (by weight) of the total weight of the pharmaceutical composition, and the filler comprises about 75% to 94% (by weight) of the total weight of the pharmaceutical composition.

[0026] The present invention also provides a pharmaceutical formulation comprising the pharmaceutical composition of the present invention.

[0027] In some preferred embodiments, the pharmaceutical formulation of the present invention is a tablet, granule, powder, sustained-release formulation, pill, capsule, lozenge, or flat capsule. In one specific embodiment, the sustained-release agent is a sustained-release microgranule. In another specific embodiment, the pharmaceutical formulation of the present invention is a tablet, capsule, or granule.

[0028] In some preferred embodiments, the present invention provides a pharmaceutical formulation comprising the pharmaceutical composition of the present invention, said pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt, solvate or crystal, disintegrant, lubricant and filler, wherein, based on the amount of the compound of formula (I), said compound of formula (I) or a pharmaceutically acceptable salt, solvate or crystal comprises about 1% to 80% (by weight) of the total weight of the pharmaceutical composition, said disintegrant comprises about 1% to 30% (by weight) of the total weight of the pharmaceutical composition, said lubricant comprises about 0% to 10% (by weight) of the total weight of the pharmaceutical composition, and said filler comprises about 0% to 95% (by weight) of the total weight of the pharmaceutical composition. More preferably, the pharmaceutical composition of the present invention comprises a compound of formula (I) or a pharmaceutically acceptable salt, solvate or crystal, disintegrant, lubricant and filler, wherein, based on the amount of the compound of formula (I), the compound of formula (I) or a pharmaceutically acceptable salt, solvate or crystal comprises about 1% to 40% (by weight) of the total weight of the pharmaceutical composition, the disintegrant comprises about 2% to 15% (by weight) of the total weight of the pharmaceutical composition, the lubricant comprises about 0.1% to 5% (by weight) of the total weight of the pharmaceutical composition, and the filler comprises about 40% to 95% (by weight) of the total weight of the pharmaceutical composition. More preferably, the pharmaceutical composition of the present invention comprises a compound of formula (I) or a pharmaceutically acceptable salt, solvate or crystal, disintegrant, lubricant and filler, wherein, based on the amount of the compound of formula (I), the compound of formula (I) or a pharmaceutically acceptable salt, solvate or crystal comprises about 2% to 20% (by weight) of the total weight of the formulation, the disintegrant comprises about 3% to 5% (by weight) of the total weight of the pharmaceutical composition, the lubricant comprises about 0.3% to 2% (by weight) of the total weight of the pharmaceutical composition, and the filler comprises about 75% to 94% (by weight) of the total weight of the pharmaceutical composition. Another aspect of the present invention provides a method for preparing the composition of the present invention, comprising mixing the components of the pharmaceutical composition of the present invention.

[0029] In some embodiments, the present invention provides a method for preparing a pharmaceutical formulation comprising a compound of formula (I) or a pharmaceutically acceptable salt, solvate, or crystallizer and disintegrant thereof, the method comprising: mixing the compound of formula (I) or a pharmaceutically acceptable salt, solvate, or crystallizer and disintegrant thereof, followed by granulation. In some specific embodiments, in the method for preparing a pharmaceutical formulation according to the present invention, the disintegrant is selected from one or more of sodium carboxymethyl starch, crospovidone, crospovidone carboxymethyl cellulose, or low-substituted hydroxypropyl cellulose.

[0030] In some preferred embodiments, the present invention provides a method for preparing a pharmaceutical formulation comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, a solvate or crystal, a filler, and a disintegrant, the method comprising: mixing the compound of formula (I) or a pharmaceutically acceptable salt thereof, a solvate or crystal, and a filler and a disintegrant, followed by granulation. In some specific embodiments, in the method for preparing a pharmaceutical formulation according to the present invention, the filler is selected from one or more of microcrystalline cellulose, powdered cellulose, magnesium carbonate, calcium sulfate dihydrate, pregelatinized starch, mannitol, starches, lactose, sugars, celluloses, and inorganic salts; the disintegrant is selected from one or more of sodium carboxymethyl starch, crospovidone, crospovidone carboxymethyl cellulose, or low-substituted hydroxypropyl cellulose.

[0031] In some preferred embodiments, the present invention provides a method for preparing a pharmaceutical formulation comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, a solvate or crystal, a lubricant, and a disintegrant, the method comprising: mixing the compound of formula (I) or a pharmaceutically acceptable salt thereof, a solvate or crystal, a disintegrant, and a lubricant, followed by granulation. In some specific embodiments, in the method for preparing a pharmaceutical formulation according to the present invention, the lubricant is selected from one or more of magnesium stearate, calcium stearate, zinc stearate, stearic acid, polyethylene glycol, talc, sodium stearate fumarate, and glyceryl behenate; the disintegrant is selected from one or more of sodium carboxymethyl starch, crospovidone, crospovidone carboxymethyl cellulose, or low-substituted hydroxypropyl cellulose.

[0032] In some other preferred embodiments, the present invention provides a method for preparing a pharmaceutical formulation comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, a solvate or crystal, a filler, a disintegrant, and a lubricant, the method comprising: mixing the compound of formula (I) or a pharmaceutically acceptable salt thereof, a solvate or crystal thereof, and the filler, disintegrant, and lubricant, followed by a granulation step. In some specific embodiments, in the method for preparing a pharmaceutical formulation according to the present invention, the filler is selected from one or more of microcrystalline cellulose, powdered cellulose, magnesium carbonate, calcium sulfate dihydrate, pregelatinized starch, mannitol, starches, lactose, sugars, celluloses, and inorganic salts; the disintegrant is selected from one or more of sodium carboxymethyl starch, crospovidone, crospovidone carboxymethyl cellulose, or low-substituted hydroxypropyl cellulose; the lubricant is selected from one or more of magnesium stearate, calcium stearate, stearic acid, zinc stearate, sodium stearate fumarate, talc, polyethylene glycol, glyceryl behenate, glyceryl monostearate, glyceryl stearate palmitate, sodium lauryl sulfate, and hydrogenated vegetable oil.

[0033] In some other preferred embodiments, the present invention provides a method for preparing the pharmaceutical formulation of the present invention, the method comprising: thoroughly mixing a compound of formula (I) or a pharmaceutically acceptable salt thereof, a solvate or a crystallizer and filler, a disintegrant and a lubricant, granulating, and encapsulating.

[0034] In some other preferred embodiments, the present invention provides a method for preparing the pharmaceutical formulation of the present invention, the method comprising: thoroughly mixing a compound of formula (I) or a pharmaceutically acceptable salt thereof, a solvate or a crystallizer and filler, a disintegrant and a lubricant, granulating, and compressing to form tablets.

[0035] In some other preferred embodiments, the present invention provides a method for preparing the pharmaceutical formulation of the present invention, the method comprising: adding fillers, disintegrants, and lubricants to a compound of formula (I) or its pharmaceutically acceptable salts, solvates, or crystals as needed, and then performing granulation by stirring, extrusion granulation, rotary granulation, spray granulation, or direct dry granulation, or the method thereof. Alternatively, microgranulation can be used. Furthermore, granulation or pulverization can be performed as needed. Furthermore, the formulation can be compressed into tablets or directly encapsulated as needed; alternatively, disintegrants, lubricants, antioxidants, colorants, etc., can be selectively added to the above-mentioned granules for compression into tablets or direct encapsulation.

[0036] In some specific embodiments, the present invention provides a method for preparing the pharmaceutical formulation of the present invention, the method comprising:

[0037] (1) Mix the compound of formula (I) or its pharmaceutically acceptable salt, solvate or crystallizer, disintegrant and optional filler and lubricant evenly;

[0038] (2) Add the mixture from step (1) to the tablet press, compress it into tablets, and then crush it.

[0039] (3) Dry granulation of the mixture from step (2);

[0040] (4) Optionally, the particles, disintegrant, and lubricant from step (3) are mixed evenly;

[0041] (5) Prepare a formulation from the mixture of step (4).

[0042] In some specific embodiments, the present invention provides a method for preparing the pharmaceutical formulation of the present invention, the method comprising:

[0043] (1) Mix the compound of formula (I) or its pharmaceutically acceptable salt, solvate or crystallizer, disintegrant and optional filler and lubricant evenly;

[0044] (2) Add the mixture from step (1) to the tablet press, compress it into tablets, and then crush it.

[0045] (3) Dry granulation of the mixture from step (2);

[0046] (4) Optionally, the particles, disintegrant, and lubricant from step (3) are mixed evenly;

[0047] (5) Pour the mixture from step (4) into the capsule filling machine to fill the capsules.

[0048] In some specific embodiments, the present invention provides a method for preparing the pharmaceutical formulation of the present invention, the method comprising:

[0049] (1) Mix the compound of formula (I) or its pharmaceutically acceptable salt, solvate or crystallizer, disintegrant and optional filler and lubricant evenly;

[0050] (2) Add the mixture from step (1) to the tablet press, compress it into tablets, and then crush it.

[0051] (3) Dry granulation of the mixture from step (2);

[0052] (4) Optionally, the particles, disintegrant, and lubricant from step (3) are mixed evenly;

[0053] (5) Pour the mixture from step (4) into a tablet press and compress it into tablets.

[0054] In some embodiments, the pharmaceutical composition according to the invention comprises a compound of formula (I) or a pharmaceutically acceptable salt, solvate, or an inorganic or organic salt of the compound of formula (I) crystallized therein. Preferably, the pharmaceutically acceptable salt may be a hydrochloride, hydrobromide, phosphate, aminosulfonate, nitrate, p-toluenesulfonate, benzenesulfonate, p-aminobenzenesulfonate, methanesulfonate, sulfate, acetate, oxalate, phenylacetate, propionate, malonate, trifluoroacetate, succinate, glycolate, stearate, ascorbate, bis(hydroxynaphthyl)ate, hydroxymaleate, glutamate, benzoate, salicylate, 2-acetoxybenzoate, fumarate, ethanedisulfonate, oxalate, hydroxyethanesulfonate, citrate, D-gluconate, lactate, L-malate, succinate, L-tartrate, fumarate, α-ketoglutarate, hippurate, maleate, or D-tartrate.

[0055] Another aspect of the invention provides a method for using the compositions of the invention to treat PRMT5-mediated diseases and their use in the preparation of medicaments for treating PRMT5-mediated diseases, wherein the PRMT5-mediated diseases include, but are not limited to, proliferative diseases, metabolic diseases, or hematologic disorders. In some embodiments, the PRMT5-mediated diseases of the present invention are cancer.

[0056] In some embodiments, the PRMT5-mediated diseases described in this invention include, but are not limited to: acoustic neuroma, adenocarcinoma, adrenal carcinoma, anal cancer, angiosarcoma (e.g., lymphangiosarcoma, lymphangioendothelial sarcoma, angiosarcoma), adnexal cancer, benign monoclonal gammopathy, biliary cancer (e.g., cholangiocarcinoma), bladder cancer, breast cancer (e.g., breast adenocarcinoma, papillary breast carcinoma, breast cancer, medullary breast carcinoma, triple-negative breast cancer), brain cancer (e.g., meningioma; glioma, e.g., astrocytoma, oligodendroglioma; medulloblastoma), bronchial cancer, carcinoid tumor, cervical cancer (e.g., cervical adenocarcinoma), choriocarcinoma, craniopharyngioma, colorectal cancer (e.g., colon cancer, rectal cancer, colorectal adenocarcinoma), epithelial cancer, ependymoma, endothelial sarcoma (e.g., Kaposi's sarcoma). Sarcoma, multiple idiopathic hemorrhagic sarcomas, endometrial cancer (e.g., uterine cancer, uterine sarcoma), esophageal cancer (e.g., esophageal adenocarcinoma, Barrett's adenocarcinoma), Ewing sarcoma Cancers including sarcoma, ocular cancer (e.g., intraocular melanoma, retinoblastoma), familial eosinophilia, gallbladder cancer, gastric cancer (e.g., gastric adenocarcinoma), gastrointestinal stromal tumors (GIST), head and neck cancers (e.g., head and neck squamous cell carcinoma, oral cancer (e.g., oral squamous cell carcinoma (OSCC), pharyngeal cancer (e.g., laryngeal cancer, pharyngeal cancer, nasopharyngeal cancer, oropharyngeal cancer)), hematopoietic system cancers (e.g., leukemia such as acute lymphoblastic leukemia (ALL) (e.g., B-cell ALL, T-cell ALL), acute myeloid leukemia (AML) (e.g., B-cell AML, T-cell AML), chronic myeloid leukemia (CML) (e.g., B-cell CML, T-cell CML), and chronic lymphocytic leukemia (CLL) (e.g., B-cell CML). L-cell and T-cell CLL); lymphomas such as Hodgkin lymphoma (HL) (e.g., B-cell HL, T-cell HL) and non-Hodgkin lymphoma (NHL) (e.g., B-cell NHL such as diffuse large cell lymphoma (DLCL) (e.g., diffuse large B-cell lymphoma (DLBCL)), follicular lymphoma, chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL / SLL), mantle cell lymphoma (MCL), marginal zone B-cell lymphoma (e.g., mucosa-associated lymphoid tissue (MALT) lymphoma, nodular marginal zone B-cell lymphoma, splenic marginal zone B-cell lymphoma), primary mediastinal B-cell lymphoma, Burkitt lymphoma, lymphoplasmacytic lymphoma (i.e., "Woldanstrom macroglobulinemia") macroglobulinemia, hairy cell leukemia (HCL), immunoblastic large cell lymphoma, precursor B-cell lymphoblastic lymphoma, and primary central nervous system (CNS) lymphoma; and T-cell NHL such as precursor T-cell lymphoblastic lymphoma / leukemia, peripheral T-cell lymphoma (PTCL) (e.g., cutaneous T-cell lymphoma (CTCL) (e.g., mycosis fungiodes, Sezary syndrome), angioimmunoblastic T-cell lymphoma, extranodular natural killer T-cell lymphoma, enteropathy-type T-cell lymphoma, subcutaneous panniculitis-like T-cell lymphoma, anaplastic large cell lymphoma); and mixtures of one or more leukemias / lymphomas as described above;And multiple myeloma (MM), heavy chain diseases (e.g., alpha chain disease, gamma chain disease, μ chain disease), angioblastoma, inflammatory myofibroblastoma, immune cell amyloidosis, renal cell carcinoma (e.g., nephroblastoma, also known as Wilms' tumor), hepatocellular carcinoma (e.g., hepatocellular carcinoma (HCC), malignant hepatocellular carcinoma), lung cancer (e.g., bronchial carcinoma, small cell lung cancer (SCLC), non-small cell lung cancer (NSCLC), lung adenocarcinoma), leiomyosarcoma (LMS), mastocytosis (e.g., generalized mastocytosis), myelodysplastic syndrome (MDS), mesothelioma, myeloproliferative disorders (MPD) (e.g., polycythemia vera (PV), idiopathic thrombocythemia (ET), idiopathic extramedullary metaplasia (AMM)). Named myelofibrosis (MF), chronic idiopathic myelofibrosis, chronic myeloid leukemia (CML), chronic neutrophilic leukemia (CNL), eosinophilic leukocytosis (HES), neuroblastoma, neurofibroma (e.g., type 1 or 2 multiple neurofibroma (NF), Schwannomatosis), neuroendocrine carcinoma (e.g., gastrointestinal pancreatic neuroendocrine tumor (GEP-NET), carcinoid tumor), osteosarcoma, ovarian cancer (e.g., cystadenocarcinoma, ovarian embryonal carcinoma, ovarian adenocarcinoma, ovarian clear cell carcinoma, ovarian serous cystadenocarcinoma), papillary adenocarcinoma, pancreatic cancer (e.g., pancreatic adenocarcinoma, intraductal papillary myxoma (IPMN), islet cell tumor), penile cancer (e.g., Paget's disease of the penis and scrotum). Diseases including pineal gland tumors, primary neuroectodermal tumors (PNT), prostate cancer (e.g., prostate adenocarcinoma), rectal cancer, rhabdomyosarcoma, salivary duct cancer, skin cancer (e.g., squamous cell carcinoma (SCC), keratoacanthoma (KA), melanoma, basal cell carcinoma (BCC)), small bowel cancer (e.g., adnexal cancer), soft tissue sarcomas (e.g., malignant fibrous histiocytoma (MFH), liposarcoma, malignant peripheral nerve sheath tumor (MPNST), chondrosarcoma, fibrosarcoma, myxosarcoma), sebaceous gland cancer, sweat gland cancer, synovial tumors, testicular cancer (e.g., seminoma, embryonal testicular carcinoma), thyroid cancer (e.g., papillary thyroid carcinoma, papillary thyroid carcinoma (PTC), medullary thyroid carcinoma), urethral cancer, vaginal cancer, and vulvar cancer (e.g., vulvar Paget's disease), medulloblastoma, adenoid cystic carcinoma, melanoma, and glioblastoma.

[0057] In some embodiments, the PRMT5-mediated diseases described in this invention include metabolic conditions such as diabetes or obesity.

[0058] In some embodiments, the PRMT5-mediated diseases described in this invention include hemoglobinopathies such as sickle cell disease or β-thalassemia.

[0059] In some embodiments, the PRMT5-mediated diseases described in this invention include inflammatory and autoimmune diseases.

[0060] In some preferred embodiments, the present invention provides a method for treating PRMT5-mediated diseases using a compound of general formula I or an isomer thereof, a pharmaceutically acceptable salt, a solvate, a crystal or a prodrug, or a pharmaceutical composition comprising thereof, and its use in the preparation of a medicament for treating PRMT5-mediated diseases, wherein the PRMT5-mediated diseases include, but are not limited to: breast cancer, esophageal cancer, bladder cancer, lung cancer, hematopoietic system cancers, lymphoma, medulloblastoma, medulloblastoma, rectal adenocarcinoma, colon cancer, gastric cancer, pancreatic cancer, liver cancer, adenoid cystic carcinoma, prostate cancer, lung cancer, head and neck squamous cell carcinoma, brain cancer, hepatocellular carcinoma, melanoma, oligodendroglioma, glioblastoma, testicular cancer, ovarian clear cell carcinoma, ovarian serous cystadenocarcinoma, thyroid cancer, multiple myeloma (AML), renal cell carcinoma, mantle cell lymphoma, triple-negative breast cancer, non-small cell lung cancer, hemoglobinopathies, diabetes, and obesity.

[0061] In the pharmaceutical compositions of the present invention, any form or amorphous compound of formula (I) can be used, and the resulting formulation exhibits very good stability. In other embodiments, the crystalline form of the compound of formula (I) is used to prepare the pharmaceutical compositions of the present invention.

[0062] The pharmaceutical composition provided by this invention can be completely dissolved in vitro, has few impurities, good stability, and simplifies storage and transportation conditions.

[0063] Terminology Explanation

[0064] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention pertains.

[0065] The term "solvent" refers to the form of the compounds of this invention that form solid or liquid complexes by coordination with solvent molecules, including hydrates, ethanol compounds, acetonitrile compounds, etc.

[0066] The term "crystallization" refers to the various solid forms formed by the compounds described in this invention, including crystalline and amorphous forms. In the compounds of this invention, "hydrogen," "carbon," and "oxygen" include all their isotopes. Isotopes should be understood to include those atoms having the same number of atoms but different mass numbers. For example, isotopes of hydrogen include protium, tritium, and deuterium, and isotopes of carbon include... 13 C and 14 C, oxygen isotopes include 16 O and 18 O etc.

[0067] The term “API” refers to (R)-7'-((2-acetyl-2-azaspiro[3.3]hept-6-yl)amino)-2'-(3-(3,4-dihydroisoquinoline-2(1H)-yl)-2-hydroxypropyl)-2',3'-dihydro-1'H-spiro[cyclopropane-1,4'-[2,6]naphthidine]-1'-one. Detailed Implementation

[0068] The following representative embodiments are provided to better illustrate the present invention and are not intended to limit the scope of protection of the present invention. Unless otherwise specified, all materials used in the following embodiments are commercially available.

[0069] Example 1: Preparation of (R)-7'-((2-acetyl-2-azaspiro[3.3]hept-6-yl)amino)-2'-(3-(3,4-dihydroisoquinoline-2(1H)-yl)-2-hydroxypropyl)-2',3'-dihydro-1'H-spiro[cyclopropane-1,4'-[2,6]naphthidium]-1'-one

[0070]

[0071] Step 1: Preparation of (R)-2-(ethylene oxide-2-ylmethyl)-1,2,3,4-tetrahydroisoquinoline maleate

[0072]

[0073] Anhydrous ethanol (4.26 kg) and R-(-)-epimylochloropropane (0.75 kg, 8.11 mol) were added to a 50 L glass reactor. Then, 1,2,3,4-tetrahydroisoquinoline (0.90 kg, 6.77 mol) was added dropwise, keeping the reaction temperature below 30 °C. After the addition was complete, the reaction was maintained at 25 °C ± 5 °C for 6 h. Potassium carbonate (1.87 kg, 13.53 mol) was then added, and the reaction was maintained at 25 °C ± 5 °C for 2 h. After the reaction was complete, the mixture was filtered, and the reactor was rinsed with anhydrous ethanol (2.13 kg). The rinse solution was used to wash the filter cake. The filtrate was then transferred to a 50L glass reactor, and maleic acid (0.86kg, 7.41mol) was slowly added. After stirring at room temperature for 0.5h, the mixture was cooled to 5℃±5℃ and allowed to crystallize for more than 8h. The mixture was then filtered, and the reactor was washed with anhydrous ethanol (0.71kg). The washing liquid was used to rinse the filter cake, which was then vacuum dried at 40℃±5℃ for more than 12h to obtain 1.59kg of solid, with a yield of 77.1%.

[0074] Step 2, Preparation of (R)-7'-chloro-2'-(3-(3,4-dihydroisoquinoline-2(1H)-yl)-2-hydroxypropyl)-2',3'-dihydro-1'H-spiro[cyclopropane-1,4'-[2,6]naphthidium]-1'-one

[0075]

[0076] Ethyl acetate (6.44 kg) and (R)-2-(ethylene oxide-2-ylmethyl)-1,2,3,4-tetrahydroisoquinoline maleate (1.43 kg, 4.68 mol) were added to a 50 L glass reactor and stirred until homogeneous at room temperature. Then, triethylamine (1.18 kg, 11.70 mol) was added and stirred at room temperature for 0.5 h. Purified water (7.14 kg) was then added and stirred for 1 hour until the layers separated. The organic layer was washed twice with purified water (7.14 kg), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to dryness to obtain a red liquid.

[0077] N,N-dimethylformamide (4.91 kg), the above-mentioned red liquid, 7'-chloro-2',3'-dihydro-1'H-spiro[cyclopropane-1,4'-[2,6]naphthidine]-1'-one (0.65 kg, 3.12 mol) and cesium carbonate (2.03 kg, 6.24 mol) were added to a 10 L glass reactor. The reaction system was then heated to 95 °C ± 5 °C and reacted for 1 h. After the reaction was complete, the reaction system was cooled to 25 °C ± 5 °C, filtered, and the filter cake was washed with ethyl acetate (4.69 kg). The filtrate was transferred to a 50L glass reactor, washed with water (10.40 kg), allowed to stand and separate into layers. The aqueous layer was extracted with ethyl acetate (4.69 kg), allowed to stand and separate into layers, and the organic layers were combined. The organic layers were washed with water (10.40 kg), allowed to stand and separate into layers, and dried with anhydrous sodium sulfate. The mixture was filtered, concentrated to dryness, and then transferred to a 10L glass reactor with ethyl acetate (1.17 kg). Heptane (1.33 kg) was added, and the mixture was cooled to 10℃±5℃ and stirred for at least 3 hours. The mixture was filtered, and the reactor was rinsed with heptane (0.44 kg). The rinsing solution was used to wash the filter cake. The filter cake was dried under vacuum at 40℃±5℃ for at least 12 hours to obtain 0.95 kg of solid, with a yield of 76.6%.

[0078] Step 3: Preparation of (R)-6-((2'-(3-(3,4-dihydroisoquinoline-2(1H)-yl)-2-hydroxypropyl)-1'-oxo-2',3'-dihydro-1'H-spiro[cyclopropane-1,4'-[2,6]naphthidium]-7'-yl)amino)-2-azaspiro[3.3]heptane-2-carboxylic acid tert-butyl ester

[0079]

[0080] Tetrahydrofuran (8.16 kg), (R)-7'-chloro-2'-(3-(3,4-dihydroisoquinoline-2(1H)-yl)-2-hydroxypropyl)-2',3'-dihydro-1'H-spiro[cyclopropane-1,4'-[2,6]naphthidine]-1'-one (0.92 kg, 2.31 mol), and tert-butyl were added to a 10 L glass reactor. 6-Amino-2-azaspiro[3.3]heptane-2-carboxylic acid tert-butyl ester (0.59 kg, 2.78 mol), tris(dibenzylideneacetone)dipalladium (0.04 kg, 0.046 mol), 2-di-tert-butylphospho-2',4',6'-triisopropylbiphenyl (0.08 kg, 0.184 mol) and sodium tert-butoxide (0.44 kg, 4.62 mol) were used. The air was then replaced with nitrogen. The reaction solution was then heated to 65℃±5℃ and reacted for 1 h. After the reaction was completed, the reaction solution was cooled to 25℃±5℃, filtered, and the filter cake was washed with dichloromethane (12.19 kg). The filtrate was transferred to a 50L glass reactor and the organic layer was washed three times with purified water (9.20 kg). Then, anhydrous sodium sulfate (1.84 kg) was added to the organic layer to dry it. The mixture was filtered, concentrated to dryness, and ethyl acetate (5.81 kg) was added. The mixture was then transferred to a 50L glass reactor and n-heptane (8.81 kg) was added. The mixture was stirred at room temperature for more than 8 hours and filtered. The filter cake was dried under vacuum at 35℃±5℃ for more than 12 hours to obtain 1.17 kg of solid, with a yield of 88.3%.

[0081] Step 4: Preparation of (R)-7'-((2-azaspiro[3.3]hept-6-yl)amino)-2'-(3-(3,4-dihydroisoquinoline-2(1H)-yl)-2-hydroxypropyl)-2',3'-dihydro-1'H-spiro[cyclopropane-1,4'-[2,6]naphthidium]-1'-one

[0082]

[0083] Dichloromethane (6.04 kg) and (R)-6-((2'-(3-(3,4-dihydroisoquinoline-2(1H)-yl)-2-hydroxypropyl)-1'-oxo-2',3'-dihydro-1'H-spiro[cyclopropane-1,4'-[2,6]naphthidine]-7'-yl)amino)-2-azaspiro[3,3]heptane-2-carboxylic acid tert-butyl ester (1.14 kg, 2.00 mol) were added to a 10 L glass reactor. The reaction system was then cooled to 5 °C ± 5 °C, and trifluoroacetic acid (3.50 kg) was added dropwise, while controlling the internal temperature of the reaction system to not exceed 30 °C. After the addition was complete, the reaction was maintained at 25℃±5℃ for 1 hour. After the reaction was complete, the reaction solution was concentrated, dissolved in purified water (5.70 kg), and transferred to a 50 L glass reactor. Methyl tert-butyl ether (4.22 kg) was added, and the mixture was stirred to separate the layers. The organic layer was washed twice with purified water (5.70 kg), and the aqueous layers were combined and transferred to a 50 L glass reactor. Acetonitrile (4.48 kg) was added, and the pH was adjusted to 8-9 with 2M sodium hydroxide aqueous solution at 25℃±5℃. Then, dichloromethane (30.21 kg) was added for extraction. Anhydrous sodium sulfate was added to the organic layer, and the mixture was filtered. The filtrate was transferred to a 50 L glass reactor, and mercaptosilica gel (0.06 kg) was added. The mixture was stirred at 25℃±5℃ for 0.5 hours, filtered, and concentrated to dryness. The solid was dried under vacuum at 35℃±5℃ for more than 12 hours to obtain 0.898 kg of solid, with a yield of 95.4%.

[0084] Step 5, Preparation of (R)-7'-((2-acetyl-2-azaspiro[3.3]hept-6-yl)amino)-2'-(3-(3,4-dihydroisoquinoline-2(1H)-yl)-2-hydroxypropyl)-2',3'-dihydro-1'H-spiro[cyclopropane-1,4'-[2,6]naphthidium]-1'-one

[0085]

[0086] Dichloromethane (11.79 kg), (R)-7'-((2-azaspiro[3.3]hept-6-yl)amino)-2'-(3-(3,4-dihydroisoquinoline-2(1H)-yl)-2-hydroxypropyl)-2',3'-dihydro-1'H-spiro[cyclopropane-1,4'-[2,6]naphthidium]-1'-one (0.89 kg, 1.88 mol), and N,N-diisopropylethylamine (0.49 kg, 3.76 mol) were added to a 50 L glass reactor. The reaction system was then cooled to 0 °C ± 5 °C, and acetic anhydride (0.16 kg, 1.69 mol) in dichloromethane was added dropwise. Add 1.18 kg of solution and control the temperature of the reaction system to not exceed 5℃. After the addition is complete, maintain the reaction temperature at 0℃±5℃ for 0.5 h. After the reaction is complete, add 0.014 kg of sodium hydroxide and 8.90 kg of water solution, stir and let stand to separate the layers. Wash the organic layer twice with purified water (8.90 kg), dry it with anhydrous sodium sulfate, filter, concentrate to dryness, dissolve it in dichloromethane (1.18 kg), and then separate and purify it by column chromatography (eluent: methanol / dichloromethane = 1 / 20). Collect the column liquid and concentrate it to dryness. Dry the solid under vacuum at 35℃±5℃ for more than 12 hours to obtain 0.655 kg of solid, with a yield of 67.6%.

[0087] Step 6, Purification of (R)-7'-((2-acetyl-2-azaspiro[3.3]hept-6-yl)amino)-2'-(3-(3,4-dihydroisoquinoline-2(1H)-yl)-2-hydroxypropyl)-2',3'-dihydro-1'H-spiro[cyclopropane-1,4'-[2,6]naphthidium]-1'-one

[0088]

[0089] Ethyl acetate (2.62 kg) was added to a 20 L glass reactor, followed by (R)-7'-((2-acetyl-2-azaspiro[3.3]hept-6-yl)amino)-2'-(3-(3,4-dihydroisoquinoline-2(1H)-yl)-2-hydroxypropyl)-2',3'-dihydro-1'H-spiro[cyclopropane-1,4'-[2,6]naphthidine]-1'-one (0.58 kg) prepared in the previous steps. The mixture was heated to 75 °C ± 5 °C and stirred for 3 hours under a nitrogen atmosphere. The reaction system was then cooled to 25 °C ± 5 °C and stirred to allow crystallization for 3 hours. The mixture was filtered, and the reactor was rinsed with ethyl acetate (0.26 kg). The rinse solution was used to wash the filter cake. The filter cake was then dried under vacuum at 35 °C ± 5 °C for at least 12 hours to obtain 0.49 kg of solid, with a yield of 84.5%. 1H NMR(400MHz,DMSO-d6)δ7.71(s,1H),7.00-7.15(m,4H),6.87(m,1H),4.78 (s,1H),4.16(s,1H),4.04-4.10(m,3H),3.88(m,1H),3.70-3.80(m,3H),3. 61-3.63(m,2H),2.80-2.83(m,2H),2.70-2.72(m,2H),2.18-2.20(m,1H), 1.98-2.02(m,4H),1.72(s,3H),1.24-1.30(m,4H),0.94-1.0(m,4H).LC-MS m / z:[M+H] + =516.3.

[0090] Example 2-13

[0091] Tables 1 to 2 show Examples 2-13, which are formulations made using the compound of formula (I) (abbreviated as API) prepared in Example 1 of the present invention and various disintegrants, fillers, wetting agents, lubricants, etc.

[0092] Table 1

[0093]

[0094] Table 2

[0095]

[0096]

[0097] " / " indicates that no symbol was added.

[0098] The preparation methods of Examples 2-13 are as follows:

[0099] (1) Pretreatment and weighing of raw materials and auxiliary materials: API, microcrystalline cellulose VIVAPUR 102, lactose FLOWLAC 100, mannitol 160C, croscarmellose sodium SD-711, magnesium stearate, carboxymethyl starch sodium Vivastar P, and low-substituted hydroxypropyl cellulose LH-21 were weighed according to the prescription amounts of Examples 2-13 shown in Table 1-2, and passed through a 60-mesh sieve respectively;

[0100] (2) According to Examples 2-13 shown in Table 1-2, first premix the lactose FLOWLAC 100 or mannitol 160C and API in step (1) for 2 min, then add microcrystalline cellulose and cross-linked sodium carboxymethyl cellulose SD-711 or sodium carboxymethyl starch Vivastar P or low-substituted hydroxypropyl cellulose LH-21 and continue mixing for 10 min.

[0101] (3) Add the mixture from step (2) to a single-punch tablet press, manually compress it into tablets, and then crush it.

[0102] (4) The mixture from step (3) is granulated dry using a 30-mesh sieve;

[0103] (5) Mix the dry granules from step (4) and the prescribed amount of magnesium stearate in a self-sealing bag by manually shaking for 2 minutes, and then compress them into tablets using a DP30A single punch tablet press.

[0104] Comparative Example 1: (S)-6-((1-acetylpiperidin-4-yl)amino)-N-(3-(3,4-dihydroisoquinoline-2(1H)-yl)-2-hydroxypropyl)pyrimidin-4-carboxamide (Compound A)

[0105]

[0106] Compound A, represented by the above formula, was prepared according to the method disclosed in WO2014 / 100719 (PCT / US2013 / 077235) for compound 208, and identified by proton NMR and mass spectrometry.

[0107] Comparative Example 2: (R)-7'-((1-acetylpiperidin-4-yl)amino)-2'-(3-(3,4-dihydroisoquinoline-2(1H)-yl)-2-hydroxypropyl)-2',3'-dihydro-1'H-spiro[cyclopropane-1,4'-isoquinoline]-1'-one (Compound B)

[0108]

[0109] Step 1: Preparation of methyl 2-(1-cyanocyclopropyl)benzoate

[0110]

[0111] Sodium hydride (4.46 g, 111 mmol) was placed in a three-necked flask, and 20 mL of anhydrous N,N-dimethylformamide was added at 0 °C. The mixture was stirred for 5 min, and then 80 mL of an N,N-dimethylformamide solution containing methyl 2-(cyanomethyl)benzoate (7.80 g, 44.6 mmol) was slowly added. The mixture was stirred at 0 °C for 30 min, and then 1,2-dibromoethane (10.0 g, 53.5 mmol) was slowly added dropwise. After the addition was complete, the mixture was allowed to stand at room temperature for 2 h. After the reaction was complete, 20 mL of saturated ammonium chloride solution was added to quench the reaction. The mixture was extracted with ethyl acetate (30 mL × 3), and the organic phases were combined and washed with water (10 mL × 3).

[0112] 2) The compound was washed with saturated brine, dried over anhydrous sodium sulfate, and the solvent was removed under reduced pressure. The title compound was then separated by column chromatography. LC-MS m / z: [M+H] + =202.

[0113] Step 2: Preparation of 2',3'-dihydro-1'H-spiro[cyclopropane-1,4'-isoquinoline]-1'-one

[0114]

[0115] Methyl 2-(1-cyanocyclopropyl)benzoate (13.3 g, 66.1 mmol) was dissolved in 150 mL of anhydrous ethanol. Cobalt chloride hexahydrate (31.5 g, 132 mmol) was added, followed by the addition of sodium borohydride (7.54 g, 198 mmol) in portions at 0 °C. The reaction mixture was then allowed to react at room temperature for 1 h, followed by reaction at 80 °C for 2 h. After the reaction was complete, the mixture was filtered, and the solvent was removed from the filtrate under reduced pressure. The title compound was obtained by column chromatography. LC-MS m / z:

[0116] [M+H] + =174.

[0117] Step 3: Preparation of 7'-nitro-2',3'-dihydro-1'H-spiro[cyclopropane-1,4'-isoquinoline]-1'-one

[0118]

[0119] 2',3'-dihydro-1'H-spiro[cyclopropane-1,4'-isoquinoline]-1'-one (6.33 g, 36.6 mmol) was dissolved in concentrated sulfuric acid (30 mL) cooled in an ice bath. Potassium nitrate (3.69 g, 36.6 mmol) was added in portions at -10 °C, and the reaction was allowed to proceed to room temperature for 1 h. After the reaction was complete, the solution was poured into ice water, and a solid precipitated. The solid was filtered, and the filter cake was dried to give the title compound. LC-MS m / z: [M+H] + =219.

[0120] Step 4: Preparation of 7'-amino-2',3'-dihydro-1'H-spiro[cyclopropane-1,4'-isoquinoline]-1'-one

[0121]

[0122] 7'-nitro-2',3'-dihydro-1'H-spiro[cyclopropane-1,4'-isoquinoline]-1'-one (4.57 g, 210 mmol) was dissolved in a mixed solvent of 40 mL ethanol and 10 mL water. Iron powder (2.93 g, 52.4 mmol) and ammonium chloride (3.33 g, 62.9 mmol) were added, and the mixture was reacted at 80 °C for 2 h. After the reaction was complete, the mixture was filtered, the filtrate was concentrated under reduced pressure, extracted with dichloromethane (30 mL × 3), the organic phases were combined, dried over anhydrous sodium sulfate, the solvent was removed under reduced pressure, and the title compound was obtained by column chromatography. LC-MS m / z: [M+H] + =189.

[0123] Step 5: Preparation of 7'-((1-acetylpiperidin-4-yl)amino)-2',3'-dihydro-1'H-spiro[cyclopropane-1,4'-isoquinoline]-1'-one

[0124]

[0125] 7'-Amino-2',3'-dihydro-1'H-spiro[cyclopropane-1,4'-isoquinoline]-1'-one (1.55 g, 8.24 mmol) and 1-acetyl-4-piperidinone (1.16 g, 8.24 mmol) were dissolved in 20 mL of methanol, and glacial acetic acid (0.472 mL, 8.24 mmol) was added. The reaction was allowed to proceed at room temperature for 2 h. Then, a borane-pyridine complex (1.24 mL, 12.4 mmol) was slowly added dropwise at 0 °C, and the mixture was allowed to stand at room temperature for 2 h. After the reaction was complete, the pH was adjusted to alkaline with saturated sodium bicarbonate solution, and the mixture was extracted with dichloromethane (20 mL × 3). The organic phases were combined, dried over anhydrous sodium sulfate, and the solvent was removed under reduced pressure. The title compound was obtained by column chromatography. LC-MS m / z: [M+H] + =314.

[0126] Step 6: Preparation of (R)-7'-((1-acetylpiperidin-4-yl)amino)-2'-(3-(3,4-dihydroisoquinoline-2(1H)-yl)-2-hydroxypropyl)-2',3'-dihydro-1'H-spiro[cyclopropane-1,4'-isoquinoline]-1'-one (compound B)

[0127]

[0128] 7'-((1-acetylpiperidin-4-yl)amino)-2',3'-dihydro-1'H-spiro[cyclopropane-1,4'-isoquinoline]-1'-one (1.56 g, 4.98 mmol) was dissolved in 10 mL of anhydrous N,N-dimethylformamide solution. Sodium hydride (0.299 g, 7.48 mmol) was added in portions at 0 °C, and the mixture was stirred for 30 min. Then, (R)-2-(ethylene oxide-2-ylmethyl)-1,2,3,4-tetrahydroisoquinoline (0.942 g, 4.98 mmol) in N,N-dimethylformamide solution (5 mL) was added, and the mixture was allowed to react overnight at room temperature. After the reaction was complete, 8 mL of saturated ammonium chloride solution was added to quench the reaction. The solvent was removed under reduced pressure, and the mixture was separated by column chromatography and pre-HPLC (preparative liquid chromatography) to obtain the title compound. 1H NMR(400MHz,DMSO-d6)δ7.16-7.23(m,1H),7.05-7.16(m,3H),6.99-7.05(m,1H),6.65-6.77(m, 2H),5.57(d,1H),4.75(s,1H),4.19(d,1H),3.94-4.10(m,1H),3.71-3.87(m,2H),3.62(s,2H), 3.42-3.54(m,2H),3.34-3.41(m,1H),3.11-3.25(m,2H),2.75-2.94(m,3H),2.62-2.74(m,2H), 2.36-2.48(m,2H),2.00(s,3H),1.79-1.96(m,2H),1.12-1.36(m,2H),0.75-0.97(m,4H).LC-MS m / z:[M+H] + =503.

[0129] Comparative Example 3: (R)-7'-((2-acetyl-2-azaspiro[3.3]hept-6-yl)amino)-2'-(3-(3,4-dihydroisoquinoline-2(1H)-yl)-2-hydroxypropyl)-2',3'-dihydro-1'H-spiro[cyclopropane-1,4'-isoquinoline]-1'-one (Compound C)

[0130]

[0131] Step 1: Preparation of methyl 2-(1-cyanocyclopropyl)benzoate

[0132]

[0133] Sodium hydride (4.46 g, 111 mmol) was placed in a three-necked flask, and 20 mL of anhydrous N,N-dimethylformamide was added at 0 °C. The mixture was stirred for 5 min, and then 80 mL of an N,N-dimethylformamide solution containing methyl 2-(cyanomethyl)benzoate (7.80 g, 44.6 mmol) was slowly added. The mixture was stirred at 0 °C for 30 min, and then 1,2-dibromoethane (10.0 g, 53.5 mmol) was slowly added dropwise. After the addition was complete, the mixture was allowed to react at room temperature for 2 h. After the reaction was complete, the reaction was quenched with 20 mL of saturated ammonium chloride solution, extracted with ethyl acetate (30 mL × 3), and the organic phases were combined. The mixture was washed with water (10 mL × 2), washed with saturated brine, dried over anhydrous sodium sulfate, and the solvent was removed under reduced pressure. The title compound was obtained by column chromatography. LC-MS m / z: [M+H] + =202.

[0134] Step 2: Preparation of 2',3'-dihydro-1'H-spiro[cyclopropane-1,4'-isoquinoline]-1'-one

[0135]

[0136] Methyl 2-(1-cyanocyclopropyl)benzoate (13.3 g, 66.1 mmol) was dissolved in 150 mL of anhydrous ethanol. Cobalt chloride hexahydrate (31.5 g, 132 mmol) was added, followed by the addition of sodium borohydride (7.54 g, 198 mmol) in portions at 0 °C. The reaction mixture was then allowed to react at room temperature for 1 h, followed by reaction at 80 °C for 2 h. After the reaction was complete, the mixture was filtered, and the solvent was removed from the filtrate under reduced pressure. The resulting product was then separated by column chromatography to obtain the title compound. LC-MS m / z: [M+H] + =174.

[0137] Step 3: Preparation of 7'-nitro-2',3'-dihydro-1'H-spiro[cyclopropane-1,4'-isoquinoline]-1'-one

[0138]

[0139] 2',3'-dihydro-1'H-spiro[cyclopropane-1,4'-isoquinoline]-1'-one (6.33 g, 36.6 mmol) was dissolved in concentrated sulfuric acid (30 mL) cooled in an ice bath. Potassium nitrate (3.69 g, 36.6 mmol) was added in portions at -10 °C, and the reaction was allowed to proceed to room temperature for 1 h. After the reaction was complete, the solution was poured into ice water, and a solid precipitated. The solid was filtered, and the filter cake was dried to give the title compound. LC-MS m / z: [M+H] + =219.

[0140] Step 4: Preparation of (R)-2'-(3-(3,4-dihydroisoquinoline-2(1H)-yl)-2-hydroxypropyl)-7'-nitro-2',3'-dihydro-1'H-spiro[cyclopropane-1,4'-isoquinoline]-1'-one

[0141]

[0142] 7'-nitro-2',3'-dihydro-1'H-spiro[cyclopropane-1,4'-isoquinoline]-1'-one (300 mg, 1.38 mmol) was dissolved in 10 mL of DMSO. Cesium carbonate (900 mg, 2.75 mmol) was added, and the mixture was stirred at room temperature for 0.5 h. Then, (R)-2-(ethylene oxide-2-ylmethyl)-1,2,3,4-tetrahydroisoquinoline (520 mg, 2.75 mmol) was added, and the reaction was carried out at 100 °C for 3 h. After the reaction was complete, 50 mL of water was added, and the mixture was extracted with ethyl acetate (30 mL × 3). The extract was dried over anhydrous sodium sulfate, and the solvent was removed under reduced pressure. The final product was obtained by column chromatography. LC-MS m / z: [M+H] + =408.

[0143] Step 5: Preparation of (R)-7'-amino-2'-(3-(3,4-dihydroisoquinoline-2(1H)-yl)-2-hydroxypropyl)-2',3'-dihydro-1'H-spiro[cyclopropane-1,4'-isoquinoline]-1'-one

[0144]

[0145] (R)-2'-(3-(3,4-dihydroisoquinoline-2(1H)-yl)-2-hydroxypropyl)-7'-nitro-2',3'-dihydro-1'H-spiro[cyclopropane-1,4'-isoquinoline]-1'-one (500 mg, 1.23 mmol), reduced iron powder (274 mg, 4.9 mmol), and ammonium chloride (260 mg, 4.90 mmol) were added to a mixture of 10 mL ethanol and 2 mL water, and reacted at 75 °C for 2 h. After the reaction was complete, the mixture was filtered, and the solvent was removed from the filtrate under reduced pressure. 20 mL of dichloromethane was added, and the mixture was filtered again. The solvent was removed from the filtrate under reduced pressure to obtain the title compound. LC-MS m / z: [M+H] + =378.

[0146] Step 6: Preparation of (R)-6-((2'-(3-(3,4-dihydroisoquinoline-2(1H)-yl)-2-hydroxypropyl)-1'-oxo-2',3'-dihydro-1'H-spiro[cyclopropane-1,4'-isoquinoline]-7'-yl)amino)-2-azaspiro[3.3]heptane-2-carboxylic acid tert-butyl ester

[0147]

[0148] (R)-7'-amino-2'-(3-(3,4-dihydroisoquinoline-2(1H)-yl)-2-hydroxypropyl)-2',3'-dihydro-1'H-spiro[cyclopropane-1,4'-isoquinoline]-1'-one (200 mg, 0.526 mmol) and tert-butyl 6-oxo-2-azaspiro[3.3]heptane-2-carboxylic acid (65.06 mg, 0.582 mmol) were dissolved in 5 mL of methanol. One drop of glacial acetic acid was added, and the mixture was stirred at room temperature for 0.5 h. Pyridine borane (74.0 mg, 0.796 mmol) was added dropwise in an ice bath, and the mixture was stirred at room temperature for 0.5 h. After the reaction was complete, the solvent was removed under reduced pressure, and the title compound was obtained by column chromatography. LC-MS m / z: [M+H] + =573.

[0149] Step 7: Preparation of (R)-7'-((2-azaspiro[3.3]hept-6-yl)amino)-2'-(3-(3,4-dihydroisoquinoline-2(1H)-yl)-2-hydroxypropyl)-2',3'-dihydro-1'H-spiro[cyclopropane-1,4'-isoquinoline]-1'-one

[0150]

[0151] (R)-6-((2'-(3-(3,4-dihydroisoquinoline-2(1H)-yl)-2-hydroxypropyl)-1'-oxo-2',3'-dihydro-1'H-spiro[cyclopropane-1,4'-isoquinoline]-7'-yl)amino)-2-azaspiro[3.3]heptane-2-carboxylic acid tert-butyl ester (180 mg, 0.315 mmol) was dissolved in 10 mL of hydrogen chloride methanol (4.0 mol / L) solution and stirred at room temperature for 0.5 h. After the reaction was complete, the solvent was removed by vacuum distillation to give the title compound. LC-MS m / z: [M+H] + =473.

[0152] Step 8: Preparation of (R)-7'-((2-acetyl-2-azaspiro[3.3]hept-6-yl)amino)-2'-(3-(3,4-dihydroisoquinoline-2(1H)-yl)-2-hydroxypropyl)-2',3'-dihydro-1'H-spiro[cyclopropane-1,4'-isoquinoline]-1'-one

[0153]

[0154] (R)-7'-((2-azaspiro[3.3]hept-6-yl)amino)-2'-(3-(3,4-dihydroisoquinoline-2(1H)-yl)-2-hydroxypropyl)-2',3'-dihydro-1'H-spiro[cyclopropane-1,4'-isoquinoline]-1'-one (140 mg, 0.297 mmol) was added to 10 mL of dichloromethane. Triethylamine was added until the solution was weakly alkaline and completely dissolved. Acetic anhydride (61.0 mg, 0.593 mmol) was then added, and the mixture was stirred at room temperature for 15 min. After the reaction was complete, the solvent was removed under reduced pressure, and the title compound was obtained by column chromatography. 1 HNMR(400MHz,MeOD)δ7.74(s,1H),7.31(m,1H),7.14-7.12(m,4H),7.06-7 .00(m,1H),4.25-4.23(m,1H),4.05-3.83(m,5H),3.70-3.61(m,2H),3.45 -3.37(m,2H),3.05-2.90(m,4H),2.87-2.72(m,2H),2.02-1.98(m,2H),1. 93(s,3H),1.84-1.81(m,1H),1.79-1.76(m,3H),1.34-1.02(m,4H).LC-MS m / z:[M+HCO2 - ] - =559.

[0155] Experimental Example 1: Dissolution Test of Examples 2-13

[0156] Dissolution test method: Dissolution test (HPLC method / Chinese Pharmacopoeia 2020 Edition, Part IV, General Chapters 0512, 0931, Method II).

[0157] Specific procedures: pH 6.8 phosphate buffer solution was used as the dissolution medium; volume: 900 mL; dissolution conditions: temperature 37℃±0.5℃, paddle method, rotation speed 50 rpm; sampling time points: 15 min and 45 min. The dissolution rate in pH 6.8 phosphate buffer solution is shown in Table 3.

[0158] Table 3

[0159]

[0160] Experimental results show that the formulations prepared in Examples 2-13 can all be fully dissolved in the dissolution medium of pH 6.8 phosphate buffer solution.

[0161] Experimental Example 2: Stability

[0162] The formulations obtained in Examples 2-13 above were placed under accelerated conditions (40℃±2℃, RH75%±5%), high humidity conditions (25℃ / 92.5%RH), and high temperature conditions (60℃) for testing. The test results showed that the formulations of the present invention were stable, had few impurities, and no significant changes were observed in various indicators.

[0163] The experimental results show that the (R)-7'-((2-acetyl-2-azaspiro[3.3]hept-6-yl)amino)-2'-(3-(3,4-dihydroisoquinoline-2(1H)-yl)-2-hydroxypropyl)-2',3'-dihydro-1'H-spiro[cyclopropane-1,4'-[2,6]naphthidium]-1'-one formulation containing a disintegrant of the present invention has complete dissolution, good stability, and meets the requirements for clinical use; in addition, the prepared compound of formula (I) has good absorption properties and relatively high bioavailability.

[0164] Experiment Example 3: Evaluation of the in vitro kinase activity of compounds

[0165] 1. Experimental Materials

[0166] Compounds (R)-7'-((2-acetyl-2-azaspiro[3.3]hept-6-yl)amino)-2'-(3-(3,4-dihydroisoquinoline-2(1H)-yl)-2-hydroxypropyl)-2',3'-dihydro-1'H-spiro[cyclopropane-1,4'-[2,6]naphthidine]-1'-one and compound C were prepared into 10 mM stock solutions using DMSO and then diluted to 10 concentrations for testing. The final concentrations were 10000.00 nM, 3333.33 nM, 1111.11 nM, 370.37 nM, 123.46 nM, 41.15 nM, 13.72 nM, 4.57 nM, 1.52 nM, and 0.51 nM.

[0167] Reagents and consumables: PRMT5, purchased from Active Motif, catalog number 31921; peptide substrate H4(1-21)S1ac, purchased from Jier Biochemical (Shanghai) Co., Ltd., catalog number 342095; [ 3 H]-SAM, purchased from PerkinElmer, catalog number NET155V001MC; SAM, purchased from Sigma, catalog number A7007-100MG; SAH, purchased from Sigma, catalog number A9384-25MG; DTT, purchased from Sangon Biotech (Shanghai) Co., Ltd., catalog number A620058-0005; Corning-3657, purchased from Corning, catalog number 3657; Echo Qualified 384-Well, purchased from Labcyte, catalog number P-05525; FlashPlate, purchased from PerkinElmer, catalog number SMP410J001PK.

[0168] Instruments: Scintillation counter, purchased from PerkinElmer, model MicroBeta2; Ultrasonic nanoliter liquid handling system, purchased from Labcyte, model Echo 550.

[0169] 2. Experimental Methods

[0170] 2.1. Preparation of reaction buffer and reaction termination solution: The reaction buffer solution consists of 10 mM Tris-HCl, pH 8.0; 0.01% Tween-20; and 1 mM DTT. The reaction termination solution consists of 125 μM... 3 H-SAM solution.

[0171] 2.2 Compound Preparation

[0172] 2.2.1 Compound Dilution

[0173] The compound was dissolved in 100% DMSO to prepare a 10 mM stock solution, and then diluted to the required concentration on an Echo 384 plate.

[0174] 2.2.2 Transferring the compound to a 384 reaction plate

[0175] Using an Echo 550 instrument, 250 nL of the compound was transferred from the diluted Echo 384-well plate to a 384-well reaction plate.

[0176] 2.3 Enzymatic Reactions

[0177] 2.3.1 Prepare a 1.67-fold enzyme solution

[0178] Add PRMT5 to 1 volume of reaction buffer to form 1.67 volume of enzyme solution.

[0179] 2.3.2 Prepare a 2.5-fold volume of substrate solution.

[0180] The peptide substrate and [ 3 H]-SAM was added to 1 volume of reaction buffer to form 2.5 volumes of substrate solutions (final concentrations of 100 nM and 250 nM, respectively).

[0181] 2.3.3 Add enzyme solution to 384-well plate

[0182] Add 15 μL of 1.67-fold enzyme solution to each well of a 384-well reaction plate. For control wells without enzyme activity, replace the enzyme solution with 15 μL of 1-fold reaction buffer. Centrifuge at 1000 rpm for 1 min and incubate at room temperature for 15 min.

[0183] 2.3.4 Add substrate solution to 384-well plate to initiate enzymatic reaction.

[0184] Add 10 μL of 2.5 times the amount of substrate solution to each well of a 384-well reaction plate. Centrifuge at 1000 rpm for 1 min. React at 25°C for 60 min.

[0185] 2.3.5 Termination of Enzymatic Reactions

[0186] The reaction was terminated by adding 5 μL of stop solution to each well of the 384-well reaction plate. 25 μL of the solution was transferred from each well of the plate to a flashplate and incubated at room temperature for 1 hour. The flashplate was then washed three times with 0.1% Tween-20 solution.

[0187] 2.4 MicroBeta 2 Data Reading

[0188] 2.4 Inhibition Rate Calculation

[0189] Copy the data from Microbeta 2. Convert the data into inhibition rate data. The maximum value refers to the conversion rate of the DMSO control, and the minimum value refers to the conversion rate of the enzyme-free control. Inhibition rate (%) = (maximum value - sample value) / (maximum value - minimum value) × 100%.

[0190] Import the data into GraphPad and use "log(inhibitor) vs. response -- Variable slope" to perform curve fitting and obtain the IC. 50 IC50 of some compounds 50 The results are shown in Table 4.

[0191] Table 4

[0192]

[0193] Experimental Example 4: Evaluation of the in vitro cell activity of compounds

[0194] 1. Experimental Materials

[0195] Test compounds: (R)-7'-((2-acetyl-2-azaspiro[3.3]hept-6-yl)amino)-2'-(3-(3,4-dihydroisoquinoline-2(1H)-yl)-2-hydroxypropyl)-2',3'-dihydro-1'H-spiro[cyclopropane-1,4'-[2,6]naphthidium]-1'-one and compounds A and B were prepared into 10 mM stock solutions using DMSO, and finally diluted to 8 concentrations for detection. Z-138 cells were tested. The final concentrations of the compounds tested were 33333.00 nM, 6666.60 nM, 1333.32 nM, 266.66 nM, 53.33 nM, 10.67 nM, 2.13 nM, and 0.43 nM. The final concentrations of the compounds tested in MDA-MB-468 and NCI-H358 cells were 50000 nM, 10000 nM, 2000 nM, 400 nM, 80 nM, 16 nM, 3.2 nM, and 0.64 nM.

[0196] Human mantle cell lymphoma cells Z-138, triple-negative breast cancer cells MDA-MB-468, and human non-small cell lung cancer cells NCI-H358 were purchased from the American Type Culture Collection (ATCC).

[0197] Reagents: Iscove's Modified Dulbecco's Medium (IMEM medium), catalog number ATCC 30-2005; Leibovitz's L-15 Medium (L-15 medium), catalog number Gibco 11415-064; 1640 medium, catalog number Gibco 22400089; horse serum, catalog number Gibco 16050122; Fetal Bovine Serum, catalog number Gibco10099-141; penicillin and streptomycin, catalog number Gibco 15140-122; sodium pyruvate, catalog number Gibco 11360070; CellTiter-Glo Luminescent Cell Viability Assay, catalog number Promega G7571; CCK-8 proliferation inhibition assay kit, catalog number KeyGEN KGA317.

[0198] 2. Experimental Methods

[0199] 2.1 Cell resuscitation:

[0200] 2.1.1 Z-138 Cell Thawing: Remove the Z-138 cell cryovials from the liquid nitrogen container and place them in a 37°C water bath. Gently shake to thaw them as quickly as possible. After thawing, remove the cryovials, disinfect them with alcohol swabs, unscrew the caps, aspirate the cell suspension into centrifuge tubes, add 1 mL of complete culture medium containing 10% horse serum, mix well, and centrifuge at 1000 rpm for 5 min. Discard the supernatant, add complete culture medium, and repeatedly pipette until the cells are completely dispersed and resuspended. Seed the cells at an appropriate concentration in culture dishes. Incubate at 37°C in a CO2 incubator with 5% CO2 and 95% humidified air.

[0201] 2.1.2 MDA-MB-468 Cell Thawing: Remove the MDA-MB-468 cell cryovials from the liquid nitrogen container and place them in a 37°C water bath. Gently shake to thaw them as quickly as possible. After thawing, remove the cryovials, sterilize them with alcohol swabs, unscrew the caps, aspirate the cell suspension into centrifuge tubes, add 1 mL of L-15 medium containing 10% FBS, mix well, and centrifuge at 1000 rpm for 5 min. Discard the supernatant, add complete culture medium, and repeatedly pipette until the cells are completely dispersed and resuspended. Seed the cells at an appropriate concentration in culture dishes. Incubate at 37°C in a CO2-free incubator with 95% humidified air.

[0202] 2.1.3 NCI-H358 Cell Thawing: Remove the NCI-H358 cell cryovials from the liquid nitrogen container and place them in a 37°C water bath. Gently shake to thaw them as quickly as possible. After thawing, remove the cryovials, sterilize them with alcohol swabs, unscrew the caps, aspirate the cell suspension into centrifuge tubes, add 1 mL of 1640 medium containing 10% FBS, mix well, and centrifuge at 1000 rpm for 5 min. Discard the supernatant, add complete culture medium, and repeatedly pipette until the cells are completely dispersed and resuspended. Seed the cells at an appropriate concentration in culture dishes. Incubate at 37°C in a CO2 incubator with 5% CO2 and 95% humidified air.

[0203] 2.2 Cell Culture and Passaging:

[0204] 2.2.1 Z-138 Cell Culture and Passage: When cells reach approximately 80-90% cell growth, transfer the culture medium (IMDM medium + 10% horse serum + 1% penicillin and streptomycin) to a 15 mL centrifuge tube and centrifuge at 1000 rpm for 5 min. Remove the supernatant, resuspend the cells in complete culture medium, and seed them into culture dishes at the desired density. Incubate at 37℃, 5% CO2, and 95% humidified air. Depending on cell growth, replenish the culture medium every 2-3 days or passage the cells.

[0205] 2.2.2 MDA-MB-468 Cell Culture and Passage: When cells reach approximately 80-90% cell growth, transfer the culture medium (Leibovitz's L-15 Medium + 10% FBS + 1% penicillin-streptomycin) to a 15 mL centrifuge tube and centrifuge at 1000 rpm for 5 min. Remove the supernatant, resuspend the cells in complete culture medium, and seed them into culture dishes at the desired density. Incubate at 37°C in a CO2-free incubator with 95% humidified air. Change the culture medium or passage the cells every 2-3 days depending on cell growth.

[0206] 2.2.3 NCI-H358 Cell Culture and Passage: When cells reach approximately 80-90% cell growth, transfer the culture medium (1640 medium + 10% FBS + 1% penicillin-streptomycin + 1mM sodium pyruvate) to a 15mL centrifuge tube and centrifuge at 1000rpm for 5min. Remove the supernatant, resuspend the cells in complete culture medium, and seed them into culture dishes at the desired density. Incubate in a CO2 incubator at 37℃, 5% CO2, and 95% humidified air. Change the culture medium or passage the cells every 2-3 days depending on cell growth.

[0207] 2.3 Experimental Procedure:

[0208] Day 1 of the experiment:

[0209] After passage, Z-138 cells were resuspended in complete culture medium at a density of 1000 cells / well and seeded into 96-well plates. The outermost 36 wells of the 96-well plate were filled with 200 μL of PBS to prevent excessive differences in culture conditions between the inner wells due to rapid evaporation of the culture medium at the edge. The leftmost column of the inner 60 wells were blank wells, without cells, and filled with an equal volume of PBS. The remaining 54 wells were seeded using a pipette, with each well containing 100 μL of culture medium with the corresponding cells. After seeding, the 96-well plate was tapped to ensure uniform cell suspension, and the plates were incubated at 37°C for 24 hours in a 5% CO2 incubator.

[0210] After passage, MDA-MB-468 cells were resuspended in complete culture medium at the appropriate density, 2000 cells / well, and seeded into 96-well plates. The outer ring of cells was filled with 200 μL of PBS to prevent excessive differences in culture conditions between the inner wells due to rapid evaporation of the culture medium at the edge. The leftmost column of the inner 60 wells was a blank well, without cells, and filled with an equal volume of PBS. The remaining 54 wells were seeded with cells using a multipipeline, 100 μL per well, and incubated at 37°C for 24 h in a CO2-free incubator.

[0211] After passage, NCI-H358 cells were resuspended in complete culture medium at the appropriate density (1000 cells / well) and seeded into 96-well plates. The outer ring of cells was filled with 200 μL of PBS to prevent excessive differences in culture conditions between the inner wells due to rapid evaporation of the medium at the edge. The leftmost column of the inner 60 wells was a blank well, filled with an equal volume of PBS without cells. The remaining 54 wells were seeded with cells using a multipipeline, 100 μL per well, and incubated at 37°C for 24 h in a 5% CO2 incubator.

[0212] Day 2 of the experiment:

[0213] Z-138 cells were cultured in a CO2 incubator for 7 days after adding 50 μL of (3×) drug to the original culture medium (100 μL). Two replicates were set up for each concentration group. The compound was prepared as follows: 1-2 mg of the compound was weighed in advance and prepared as a 10 mM stock solution using DMSO. The drug was diluted using complete culture medium, with a final concentration of 33333.00 nM as the initial maximum concentration. The drug was then diluted sequentially at a 1:4 ratio to seven concentration gradients: 6666.60 nM, 1333.32 nM, 266.66 nM, 53.33 nM, 10.67 nM, 2.13 nM, and 0.43 nM. ① The 10 mM stock solution was diluted 1:4 to prepare the corresponding drug solutions, resulting in eight concentrations (10 μL stock solution + 40 μL DMSO); ② 5 μL of the drug from step ① was added to 495 μL of complete culture medium to prepare the corresponding concentration (3×) (diluted 100 times).

[0214] MDA-MB-468 cells were cultured for 7 days in a CO2-free incubator after adding 100 μL of (2×) drug to the original culture medium (100 μL). Two replicates were set up for each concentration group. The compound was prepared as follows: 1-2 mg of the compound was weighed in advance and prepared as a 10 mM stock solution using DMSO. The drug was diluted using complete culture medium, starting at a maximum concentration of 50,000 nM, and then serially diluted at a 1:4 ratio to seven concentration gradients: 50,000 nM, 10,000 nM, 2,000 nM, 400 nM, 80 nM, 16 nM, 3.2 nM, and 0.64 nM. ① The 10 mM stock solution was diluted 1:4 to prepare the corresponding drug solutions, resulting in eight concentrations (10 μL drug solution + 40 μL DMSO); ② 5 μL of the drug from ① was added to 495 μL of complete culture medium to prepare the corresponding concentration (2×) (diluted 100 times).

[0215] NCI-H358 cells were cultured in a 5% CO2 incubator for 7 days after adding 100 μL of (2×) drug to the original culture medium (100 μL). Two replicates were set up for each concentration group. The cells were prepared as follows: 1-2 mg of the compound was weighed in advance and prepared as a 10 mM stock solution using DMSO. The drug was diluted using complete culture medium, starting at a maximum concentration of 50,000 nM, and then serially diluted at a 1:4 ratio to seven concentration gradients: 50,000 nM, 10,000 nM, 2,000 nM, 400 nM, 80 nM, 16 nM, 3.2 nM, and 0.64 nM. ① The 10 mM stock solution was diluted 1:4 to prepare the corresponding drug solutions, resulting in eight concentrations (10 μL drug solution + 40 μL DMSO); ② 5 μL of the drug from ① was added to 495 μL of complete culture medium to prepare the corresponding concentration (2×) (diluted 100 times).

[0216] Day 8 of the experiment:

[0217] Seven days after drug treatment, Z-138 cells were removed from the CellTiter-Glo Luminescent CellViabillity Assay 30 minutes beforehand and allowed to equilibrate to room temperature. PBS was aspirated from the blank wells, and 150 μL of complete culture medium was added. Then, 75 μL of Celltiter-Glo reagent was added to the blank wells, drug-treated wells, and DMSO wells, and the cells were shaken at room temperature for 2 minutes. After incubation at room temperature for another 10 minutes, 180 μL of the solution was transferred from each well to an opaque white plate. After removing air bubbles, the chemiluminescence signal was detected by shaking. The read sequence was set at 500 ms. Based on the AU value derived from the microplate reader, the inhibition rate of each well relative to the solvent control well was calculated: Inhibition (%) = 100 - (AU) 实验孔 –AU 空白孔) / (AU 溶剂对照孔 -AU 空白孔 *100. Based on different drug concentrations and their corresponding inhibition rates, IC50 was performed using GraghPad 5.0 software. 50 Curve plotting, data analysis, and final IC calculation. 50 The values ​​are shown in Table 5.

[0218] After treating MDA-MB-468 and NCI-H358 cells with the drug for 7 days, the culture medium in the wells was discarded, and 100 μL of complete culture medium containing CCK-8 was added (CCK-8:complete culture medium = 1:10). The first vertical row of PBS served as a blank control well, with 100 μL of CCK-8 added simultaneously. The wells were then incubated for approximately 40 min to 2 h. The optimal detection time was determined based on the color intensity of the CCK-8 (the optimal OD value for the DMSO group was around 1.0). Once the CCK-8 color developed to orange and a visible gradient appeared, the 96-well plate was removed from the incubator and allowed to equilibrate at room temperature for 5-10 minutes. The microplate reader software was opened, the detection parameters were adjusted, and the absorbance (OD value) at 450 nm was measured. The plate cap was removed, and the plate was placed horizontally in the plate holder to begin reading the values. After reading the values, the program was saved, the data was exported, and the software and computer were closed. Based on the OD values ​​exported from the microplate reader, calculate the inhibition rate of each well relative to the solvent control well: Inhibition (%) = 100 - (OD value) 实验孔 –OD 空白孔 ) / (OD 溶剂对照孔 -OD 空白孔 *100. Based on different drug concentrations and their corresponding inhibition rates, IC50 was performed using GraghPad 5.0 software. 50 Curve plotting, data analysis, and final IC calculation. 50 The values ​​are shown in Table 5.

[0219] Table 5

[0220]

[0221] As can be seen from the above experiments, the compound of formula (I) of the present invention has shown good inhibitory activity against human mantle cell lymphoma cells Z-138, triple-negative breast cancer cells MDA-MB-468, and human non-small cell lung cancer cells NCI-H358, and is very promising as a therapeutic agent for lymphoma, triple-negative breast cancer, and non-small cell lung cancer.

[0222] Experiment Example 5: Electrophysiological manual patch-clamp detection of the effect of compounds on hERG potassium channels

[0223] hERG potassium channels are a standard for drug safety screening. Blockage of hERG potassium channels can lead to cardiotoxicity and prolonged ventricular repolarization, potentially causing sudden death in severe cases. Drugs with hERG potassium channel inhibitory effects may be potential hazards in clinical use. Therefore, compounds with weak hERG potassium channel inhibition are generally considered safer. Drug-induced QT interval prolongation is associated with an increased risk of fatal ventricular arrhythmias and sudden death.

[0224] 1. Experimental Materials

[0225] Main reagents: Penicillin-streptomycin solution (100×), DMEM / F12 were purchased from Gibco; fetal bovine serum was purchased from PAA; DMSO, EGTA, and MgATP were purchased from Sigma; KCl, CaCl2·2H2O, MgCl2·6H2O, and NaCl were purchased from Sinopharm; glucose was purchased from General-reagent; HEPES was purchased from Solarbio; and quinidine was purchased from Aladdin.

[0226] Instruments: TI-S-FLU microscope purchased from Nikon; SMZ-140 / 143 microscope purchased from Motic; EPC-10 amplifier and Patchmaster V2X60 purchased from HEKA; TMC-36 anti-vibration stage purchased from TMC; MP-225 and MPC-200 controllers, ROE-200 micromanipulator, and P-97 electrode puller purchased from Sutter; VC3-8PP perfusion drug delivery system purchased from ALA.

[0227] 2 Experimental Methods

[0228] Test solvent preparation: Extracellular solution (mM): 137NaCl, 4KCl, 1.8CaCl2, 1MgCl2, 10g glucose and 10HEPES (pH 7.4); Intracellular solution (mM): 130KCl, 1MgCl2, 5EGTA, 5MgATP and 10HEPES (pH 7.2); Negative control preparation: Extracellular solution + 0.3% DMSO; Positive control: Quinidine.

[0229] Compound preparation: (R)-7'-((2-acetyl-2-azaspiro[3.3]hept-6-yl)amino)-2'-(3-(3,4-dihydroisoquinoline-2(1H)-yl)-2-hydroxypropyl)-2',3'-dihydro-1'H-spiro[cyclopropane-1,4'-[2,6]naphthidine]-1'-one and compound B were weighed and dissolved in DMSO to prepare a 10 mM stock solution. The stock solution was then diluted with DMSO to prepare secondary stock solutions with concentrations of 3.3, 1.1, 0.37, and 0.12 mM. 90 μL of each of the stock solution and secondary stock solution were diluted into 30 mL of extracellular fluid for electrophysiological detection. The final concentrations of the compounds were 30, 10, 3.3, 1.1, and 0.37 μM, and the final concentration of DMSO was 3:1000.

[0230] Stable cell culture: The cell line was derived from HEK-293 cells overexpressing hERG potassium channels, established and validated in collaboration with the laboratory of Dr. Mohamed Boutjdir at NYU School of Medicine, with technical support provided. Cells were cultured at 37°C in a 5% CO2 incubator. When the cell density reached 80% in the culture dish, the cells were pre-washed with phosphate-buffered saline (PBS), then digested with trypsin / EDTA for 2-3 min. Cell culture medium was added to stop digestion, and the cells were gently blown off and transferred to centrifuge tubes. The centrifuge tubes were centrifuged at 1000 rpm for 3 min, the supernatant was discarded, cell culture medium was added, and the cells were gently mixed by pipetting. The cells were then transferred to culture dishes for passage, or cells were dropped onto round glass slides and placed in culture dishes to allow them to adhere for experiments.

[0231] Cell culture medium composition: DMEM, 15% fetal bovine serum and 1% 100× penicillin-streptomycin.

[0232] Electrophysiological manual patch-clamp system experiments: Stable cells were seeded onto glass slides at a density of less than 50% and cultured overnight. The experimental cells were transferred to a 1 mL bath embedded in an inverted microscope platform, and extracellular fluid was perfused at a rate of 2.7 mL / min. Experiments could begin after 5 minutes of stabilization. Membrane currents were recorded using a HEKA EPC-10 patch-clamp amplifier and a PATCHMASTER acquisition system. All experiments were performed at room temperature (22-24℃). Electrodes (BF150-110-10) were straightened using a P-97 microelectrode straightener. The electrode inner diameter was 1-1.5 mm, and the water resistance after filling with internal fluid was 2-4 MΩ. The electrophysiological stimulation protocol for hERG potassium channels involves first clamping the membrane voltage to -80 mV, then applying a sustained +20 mV voltage stimulation to the cells for 2 seconds to activate the hERG potassium channels, followed by repolarization to -50 mV for 5 seconds to generate an outward tail current. Stimulation is repeated every 15 seconds. The peak value of the tail current is recorded. Whole-cell recording mode is used to record the channel current. First, extracellular fluid is perfused (approximately 2 mL per minute) and continuously recorded until the current stabilizes (run-down less than 5% within 5 minutes). The peak tail current at this point is the control current value. Next, extracellular fluid containing the test drug is perfused and continuously recorded until the inhibitory effect of the drug on the hERG current reaches a steady state. The peak tail current at this point is the current value after drug administration. The criterion for a steady state is whether the three most recent consecutive current recording lines overlap. If, after reaching a steady state, the hERG current recovers or approaches the level before drug administration after perfusion with extracellular fluid, perfusion can continue to test other concentrations or drugs. 30 μM quinidine was used as a positive control in the experiment to ensure that the cells used responded normally.

[0233] 3. Parameter analysis and data analysis statistics

[0234] This study evaluated the effect (Mean ± SE) of the test compound on hERG potassium ion channels at the test concentration by measuring the maximum current values ​​of the control group and the drug treatment group, and calculating the ratio of the maximum current value of the treatment group to the maximum current value of the control group.

[0235] Experimental data were collected using PATCHMASTER V2X60 and analyzed and statistically processed using Origin 8.5 software and Microsoft Excel. The experimental results are shown in Table 6.

[0236] Table 6

[0237]

[0238] The above experiments show that the compound of formula (I) of this invention has a mild inhibitory effect on hERG potassium channels and low cardiotoxicity, which is superior to compound B. Furthermore, compound B significantly prolonged the QT interval in isolated heart experiments, while the compound of formula (I) of this invention did not affect the QT interval in isolated heart experiments. The compound of this invention exhibits better cardiac safety.

[0239] Although the present invention has been described in detail above, those skilled in the art will understand that various modifications and changes can be made to the invention without departing from its spirit and scope. The scope of the invention is not limited to the detailed description above, but should be attributed to the claims.

Claims

1. A pharmaceutical composition comprising: (a) A compound of formula (I) or a pharmaceutically acceptable salt thereof, ; (b) a disintegrant, wherein the disintegrant is one or more of sodium carboxymethyl starch, crospovidone, crospovidone carboxymethyl cellulose, and low-substituted hydroxypropyl cellulose.

2. The pharmaceutical composition according to claim 1, further comprising a lubricant.

3. The pharmaceutical composition according to claim 2, wherein the lubricant is selected from one or more of magnesium stearate, calcium stearate, stearic acid, zinc stearate, sodium stearate fumarate, talc, polyethylene glycol, glyceryl behenate, glyceryl monostearate, glyceryl palmitate stearate, sodium lauryl sulfate, and hydrogenated vegetable oil.

4. The pharmaceutical composition according to any one of claims 1-3, further comprising a filler.

5. The pharmaceutical composition according to claim 4, wherein the filler is selected from one or more of starches, sugars, celluloses, and inorganic salts.

6. The pharmaceutical composition according to claim 4, wherein the filler is selected from one or more of microcrystalline cellulose, powdered cellulose, pregelatinized starch, mannitol, lactose, magnesium carbonate, and calcium sulfate dihydrate.

7. The pharmaceutical composition of claim 4, comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, a disintegrant, a lubricant, and a filler, wherein, based on the amount of the compound of formula (I), the compound of formula (I) or a pharmaceutically acceptable salt thereof constitutes about 1% to 80% (by weight) of the total weight of the pharmaceutical composition, the disintegrant constitutes about 1% to 30% (by weight) of the total weight of the pharmaceutical composition, the lubricant constitutes about 0% to 10% (by weight) of the total weight of the pharmaceutical composition, and the filler constitutes about 0% to 95% (by weight) of the total weight of the pharmaceutical composition.

8. The pharmaceutical composition according to claim 5 or 6, comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, a disintegrant, a lubricant, and a filler, wherein, based on the amount of the compound of formula (I), the compound of formula (I) or a pharmaceutically acceptable salt thereof constitutes about 1% to 80% (by weight) of the total weight of the pharmaceutical composition, the disintegrant constitutes about 1% to 30% (by weight) of the total weight of the pharmaceutical composition, the lubricant constitutes about 0% to 10% (by weight) of the total weight of the pharmaceutical composition, and the filler constitutes about 0% to 95% (by weight) of the total weight of the pharmaceutical composition.

9. A pharmaceutical preparation comprising the pharmaceutical composition of any one of claims 1-8.

10. The pharmaceutical preparation according to claim 9, wherein the pharmaceutical preparation is a tablet, granule, powder, pill, capsule, lozenge, or flat capsule.

11. The pharmaceutical formulation according to claim 9, wherein the pharmaceutical formulation is a sustained-release formulation.

12. A method for preparing a pharmaceutical formulation according to any one of claims 9-11, the method comprising the steps of mixing a compound of formula (I) or a pharmaceutically acceptable salt thereof with a disintegrant, and then granulating the mixture.

13. The method for preparing a pharmaceutical formulation according to claim 12, wherein the method comprises: (1) Mix the compound of formula (I) or its pharmaceutically acceptable salt, disintegrant and optional filler and lubricant evenly; (2) Add the mixture from step (1) to a tablet press, compress it into tablets, and then crush it. (3) Dry granulation of the mixture from step (2); (4) Optionally, the particles from step (3) are mixed evenly with the disintegrant and lubricant; (5) Prepare a formulation from the mixture of step (4).

14. Use of the pharmaceutical composition of any one of claims 1-8 or the pharmaceutical preparation of any one of claims 9-11 in the preparation of a medicament for treating lymphoma, triple-negative breast cancer or non-small cell lung cancer.

Citation Information

Patent Citations

  • PRMT5 inhibitors and uses thereof

    WO2014100719A2

  • Substituted tricyclic compound as PRMT5 inhibitor and application thereof

    CN114466846A